WO2008090736A1 - アルツハイマー型認知症の予防及び治療のための医薬 - Google Patents

アルツハイマー型認知症の予防及び治療のための医薬 Download PDF

Info

Publication number
WO2008090736A1
WO2008090736A1 PCT/JP2008/000059 JP2008000059W WO2008090736A1 WO 2008090736 A1 WO2008090736 A1 WO 2008090736A1 JP 2008000059 W JP2008000059 W JP 2008000059W WO 2008090736 A1 WO2008090736 A1 WO 2008090736A1
Authority
WO
WIPO (PCT)
Prior art keywords
dementia
alzheimer
prevention
treatment
pharmaceutical product
Prior art date
Application number
PCT/JP2008/000059
Other languages
English (en)
French (fr)
Inventor
Kosei Ojika
Noriyuki Matsukawa
Original Assignee
Nagoya City University
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya City University, Kowa Company, Ltd. filed Critical Nagoya City University
Priority to EP08702800A priority Critical patent/EP2111862A4/en
Priority to JP2008555001A priority patent/JPWO2008090736A1/ja
Priority to US12/523,436 priority patent/US20100035927A1/en
Publication of WO2008090736A1 publication Critical patent/WO2008090736A1/ja
Priority to US13/670,831 priority patent/US20130059888A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　アルツハイマー型認知症の予防及び／又は治療のための医薬であって、塩酸ドネペジルとバルプロ酸又はその塩との組み合わせを含む医薬。
PCT/JP2008/000059 2007-01-23 2008-01-22 アルツハイマー型認知症の予防及び治療のための医薬 WO2008090736A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08702800A EP2111862A4 (en) 2007-01-23 2008-01-22 PHARMACEUTICAL PRODUCT FOR THE PREVENTION AND TREATMENT OF MORBUS ALZHEIMER
JP2008555001A JPWO2008090736A1 (ja) 2007-01-23 2008-01-22 アルツハイマー型認知症の予防及び治療のための医薬
US12/523,436 US20100035927A1 (en) 2007-01-23 2008-01-22 Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
US13/670,831 US20130059888A1 (en) 2007-01-23 2012-11-07 Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007012671 2007-01-23
JP2007-012671 2007-01-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/670,831 Continuation US20130059888A1 (en) 2007-01-23 2012-11-07 Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia

Publications (1)

Publication Number Publication Date
WO2008090736A1 true WO2008090736A1 (ja) 2008-07-31

Family

ID=39644311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000059 WO2008090736A1 (ja) 2007-01-23 2008-01-22 アルツハイマー型認知症の予防及び治療のための医薬

Country Status (7)

Country Link
US (2) US20100035927A1 (ja)
EP (1) EP2111862A4 (ja)
JP (1) JPWO2008090736A1 (ja)
KR (1) KR20090119760A (ja)
CN (1) CN101636159A (ja)
RU (2) RU2009131745A (ja)
WO (1) WO2008090736A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9351654B2 (en) 2010-06-08 2016-05-31 Alivecor, Inc. Two electrode apparatus and methods for twelve lead ECG
US8509882B2 (en) 2010-06-08 2013-08-13 Alivecor, Inc. Heart monitoring system usable with a smartphone or computer
CN102512419A (zh) * 2011-11-10 2012-06-27 成都苑东药业有限公司 一种药物组合物及其制备方法
WO2014074913A1 (en) 2012-11-08 2014-05-15 Alivecor, Inc. Electrocardiogram signal detection
US9220430B2 (en) 2013-01-07 2015-12-29 Alivecor, Inc. Methods and systems for electrode placement
US9247911B2 (en) 2013-07-10 2016-02-02 Alivecor, Inc. Devices and methods for real-time denoising of electrocardiograms
WO2015089484A1 (en) 2013-12-12 2015-06-18 Alivecor, Inc. Methods and systems for arrhythmia tracking and scoring
ES2820923T3 (es) 2015-05-13 2021-04-22 Alivecor Inc Monitorización de discordancias

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324626A (ja) 1993-06-01 1998-12-08 Ono Pharmaceut Co Ltd ２−プロピルペンタン酸を含有する薬剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324626A (ja) 1993-06-01 1998-12-08 Ono Pharmaceut Co Ltd ２−プロピルペンタン酸を含有する薬剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AM. J. GERIATR. PSYCHIATRY, vol. 13, no. 11, 2005, pages 942
JOURNAL OF THE JAPAN PHARMACEUTICAL ASSOCIATION, vol. 58, no. 7, 2006, pages 861 - 864
N. ENGL. J. MED., vol. 355, no. 15, 2006, pages 1525
PROFENNO L. ET AL.: "A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Safety and Tolerability of Two Doses of Divalproex Sodium in Outpatients with Probable Alzheimer's Disease", CURRENT ALZHEIMER RESEARCH, vol. 2, no. 5, 2005, pages 553 - 558, XP008110058 *
See also references of EP2111862A4 *
TOGO T.: "Chiho no Yakubutsu Ryoho", SEISHIN IGAKU, vol. 46, no. 2, 2004, pages 124 - 132, XP008110075 *

Also Published As

Publication number Publication date
RU2012157328A (ru) 2014-07-10
US20130059888A1 (en) 2013-03-07
RU2009131745A (ru) 2011-02-27
EP2111862A4 (en) 2010-04-14
EP2111862A1 (en) 2009-10-28
JPWO2008090736A1 (ja) 2010-05-20
CN101636159A (zh) 2010-01-27
US20100035927A1 (en) 2010-02-11
KR20090119760A (ko) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2008090736A1 (ja) アルツハイマー型認知症の予防及び治療のための医薬
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
EP2977452A3 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2005070390A3 (en) Mitratapide oral solution
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2010067078A3 (en) 3,6-disubstituted xanthylium salts as medicaments
IL200029A0 (en) Methods for the treatment of senile dementia of the alzheimer's type
MX2015001917A (es) Composiciones farmaceuticas de memantina.
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
EP2392335A3 (en) Use of 24-norUDCA
MX2015000334A (es) Derivado de benzodioxol y metodo de preparacion y uso del mismo.
WO2010098583A2 (ko) 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2011027258A3 (en) Scented capsules
WO2008034912A3 (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
WO2007144699A3 (en) Process for the preparation of alfuzosin
WO2008078350A3 (en) Process for the preparation of fluorophenylacetic acids and derivatives thereof
WO2008050133A3 (en) Inhibition of beta-amyloid aggregation
AU2008339005A8 (en) 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880002730.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08702800

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008702800

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008555001

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097017287

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009131745

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12523436

Country of ref document: US